Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171470 · ClinicalTrials.gov registry record · Phase 3
The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.
A Phase 3 study of Dyspepsia, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00171470: Completed Phase 3 study of Dyspepsia, sponsored by Novartis.
NCT00171470 is a Phase 3 study of Dyspepsia that has completed, run by Novartis. The registered enrollment target is 60 participants, below the 71-participant average among 11 other Dyspepsia trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00171470, a Phase 3 study of Dyspepsia, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to provide initial data to assess the safety and efficacy of tegaserod use in patients with dyspepsia that are being treated with proton pump inhibitors (PPI's) for heartburn.
Conditions Studied
Interventions
- DRUG Tegaserod
Study Locations (1)
New Jersey
- http://www.novartisclinicaltrials.com/etrials/DiseaseID21/Dyspepsia-clinical-trials.go - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
What the finished NCT00171470 record still lists
NCT00171470 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 71-participant average among 11 other Dyspepsia trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Dyspepsia appearing as the primary indexed condition, and to 1 intervention - of which Tegaserod is the first listed.
NCT00171470 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00171470 about?
NCT00171470 is a clinical study titled "The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.". Study to provide initial data to assess the safety and efficacy of tegaserod use in patients with dyspepsia that are being treated with proton pump inhibitors (PPI's) for heartburn.
What is the current status of trial NCT00171470?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2005-04. Estimated completion is 2006-08.
What conditions does trial NCT00171470 study?
This clinical trial studies the following conditions: Dyspepsia.
What interventions are being tested in trial NCT00171470?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00171470?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00171470 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyspepsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00171470's enrollment target sits among peer trials
60 7th of 11 higher than 5 of 11 other Dyspepsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyspepsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
-
Visible Abdominal Distension
RECRUITING · NA
-
Zypan Functional Dyspepsia
RECRUITING · NA
-
High Resolution Gastric Mapping and Gastroduodenal Manometry
RECRUITING · NA
-
Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia
RECRUITING · NA
-
Famotidine and Antacids for Treatment of Dyspepsia
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia